Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Pasithea Therapeutics Corp. Director's Dealing 2025

Dec 1, 2025

35389_dirs_2025-12-01_e4477337-2d8e-4168-958b-19c1bca02fb0.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Pasithea Therapeutics Corp. (KTTA)
CIK: 0001841330
Period of Report: 2025-11-28

Reporting Person: Dumesnil Simon (Director)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2025-11-28 Common Stock P 33333 $0.75 Acquired 35833 Direct